Henry Hoppe
Corporate Officer/Principal presso Xenetic Biosciences (UK) Ltd.
Profilo
Henry Hoppe is currently the Vice President-Drug Development at Xenetic Biosciences (UK) Ltd.
He received his undergraduate and doctorate degrees from Massachusetts Institute of Technology in 1980.
Posizioni attive di Henry Hoppe
Società | Posizione | Inizio |
---|---|---|
Xenetic Biosciences (UK) Ltd.
Xenetic Biosciences (UK) Ltd. Pharmaceuticals: MajorHealth Technology Xenetic Biosciences (UK) Ltd. is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis on June 24, 1996 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | 14/05/2012 |
Formazione di Henry Hoppe
Massachusetts Institute of Technology | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
Xenetic Biosciences (UK) Ltd.
Xenetic Biosciences (UK) Ltd. Pharmaceuticals: MajorHealth Technology Xenetic Biosciences (UK) Ltd. is engaged in the development of drug and vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology. It provides specialist delivery solutions to improve the efficacy and performance of drugs and vaccines in a number of key medical areas including oncology. The company's product pipeline includes polyxen, imuxen and oncohist. Xenetic Biosciences was founded by Gregory Gregoriadis on June 24, 1996 and is headquartered in London, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Henry Hoppe